Related Experiment Video

Updated: Apr 16, 2026

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.8K

Oncogenic and Therapeutic Targeting of PTEN Loss in Bone Malignancies

Yongming Xi1, Yan Chen2

  • 1Department of Orthopaedics, Affiliated Hospital of Qingdao University, China.

Journal of Cellular Biochemistry
|March 17, 2015
PubMed

Insights

Loss of the PTEN tumor suppressor gene is common in many cancers. This review details PTEN

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • PTEN (phosphatase and tensin homolog) is a critical tumor suppressor.
  • It regulates cellular processes and signal transduction pathways.
  • Loss of PTEN function is implicated in various cancers, including breast, prostate, lung, gastric, colon, skin, and endometrial carcinomas.

Purpose of the Study:

  • To review the role of PTEN in bone malignancies.
  • To highlight the mechanisms of PTEN loss in cancer development.
  • To discuss therapeutic strategies targeting PTEN loss.

Main Methods:

  • Literature review of PTEN's function and alterations in bone cancers.
  • Analysis of PTEN's role in the PI3K/Akt/mTOR pathway.
  • Discussion of genetic and non-genetic mechanisms of PTEN inactivation.

Main Results:

  • PTEN loss is frequently observed in bone metastases, multiple myeloma, and osteosarcoma.
  • PTEN loss activates the oncogenic PI3K/Akt/mTOR pathway, promoting tumorigenesis and progression.
  • Mechanisms of PTEN inactivation include gene mutation, loss of heterozygosity, promoter hypermethylation, and microRNA-mediated regulation.

Conclusions:

  • PTEN plays a crucial role in suppressing bone malignancies.
  • Understanding the mechanisms of PTEN loss is vital for developing targeted therapies.
  • Targeting PTEN loss presents a promising therapeutic avenue for bone cancers.
Keywords:
AktBONE METASTASISPI3KPTENSARCOMA

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K
Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines06:00

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

7.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.8K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
12.2K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

6.5K